New Risk • Nov 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 32% per year over the past 5 years. Minor Risk Market cap is less than US$100m (HK$230.0m market cap, or US$29.6m). Reported Earnings • Aug 24
First half 2025 earnings released: EPS: NT$0.049 (vs NT$0.039 in 1H 2024) First half 2025 results: EPS: NT$0.049 (up from NT$0.039 in 1H 2024). Revenue: NT$585.3m (up 9.4% from 1H 2024). Net income: NT$48.7m (up 26% from 1H 2024). Profit margin: 8.3% (up from 7.2% in 1H 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Aug 09
Genes Tech Group Holdings Company Limited to Report First Half, 2025 Results on Aug 21, 2025 Genes Tech Group Holdings Company Limited announced that they will report first half, 2025 results on Aug 21, 2025 New Risk • Jul 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Earnings have declined by 37% per year over the past 5 years. Market cap is less than US$10m (HK$68.0m market cap, or US$8.66m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Reported Earnings • Mar 28
Full year 2024 earnings released: EPS: NT$0.024 (vs NT$0.091 in FY 2023) Full year 2024 results: EPS: NT$0.024 (down from NT$0.091 in FY 2023). Revenue: NT$932.0m (down 30% from FY 2023). Net income: NT$24.3m (down 73% from FY 2023). Profit margin: 2.6% (down from 6.8% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Announcement • Mar 25
Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 25, 2025 Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 25, 2025. Announcement • Mar 11
Genes Tech Group Holdings Company Limited to Report Fiscal Year 2024 Results on Mar 25, 2025 Genes Tech Group Holdings Company Limited announced that they will report fiscal year 2024 results on Mar 25, 2025 New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (HK$71.0m market cap, or US$9.13m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Reported Earnings • Aug 16
First half 2024 earnings released: EPS: NT$0.039 (vs NT$0.077 in 1H 2023) First half 2024 results: EPS: NT$0.039 (down from NT$0.077 in 1H 2023). Revenue: NT$535.0m (down 29% from 1H 2023). Net income: NT$38.7m (down 50% from 1H 2023). Profit margin: 7.2% (down from 10% in 1H 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year whereas the company’s share price has fallen by 41% per year. Announcement • Aug 02
Genes Tech Group Holdings Company Limited to Report First Half, 2024 Results on Aug 14, 2024 Genes Tech Group Holdings Company Limited announced that they will report first half, 2024 results on Aug 14, 2024 Board Change • Jul 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Eddie Kam was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 02
Genes Tech Group Holdings Company Limited Announces Change of Executive Directors The board of directors of Genes Tech Group Holdings Company Limited announced that Mr. Hsiao Hsi-Mao (Mr. Hsiao) has tendered his resignation as an executive director of the Company with effect from 30 June 2024 due to his retirement. Mr. Hsiao has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board announced that Mr. Chiang Ting-Kuo (Mr. Chiang) has been appointed as anexecutive director of the Company with effect from 1 July 2024. Mr. Chiang, aged 53, is currently the President of GAT Asset Taiwan Co Ltd. (GAT Asset) since September 2011. GAT Asset is a company focuses on semiconductor asset manager and equipment leasing and equipment remarketing. From July 1995 to February 2003, Mr. Chiang worked in Lam Research Co. Ltd. (Lam Research) as a Filed Service Section Manager from July 1995 to March 2000 in the Hsinchu branch and as a Senior Sales Manager from July 1998 to February 2003 in the Tainan branch responsible for business promotion and also responsible for customer machine maintenance. Lam Research principally engaged in the business of semiconductor etching machine manufacturing and trading. From April 2003 to March 2011, he worked in Macquarie Asia PTE Ltd. -- Taiwan Branch (Macquarie) as Director of Sales -- Asia mainly to support customer to managementoperation risk. Macquarie focuses on semiconductor equipment leasing, assisting customers in handling idle equipment and used equipment sale. Mr. Chiang graduated from National Taiwan Ocean University in Taiwan with a Bachelor of Science degree in Electrical Engineering in June 1993. Mr. Chiang shall hold office until the next general meeting of the Company following hisappointment and shall then be eligible for re-election at that meeting in accordance with the articles of association of the Company (the Articles), and is subject to the provisions on retirement by rotation and re-election of directors in accordance with the Articles. Announcement • Mar 22
Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 26, 2024 Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 26, 2024. Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: NT$0.091 (vs NT$0.08 loss in FY 2022) Full year 2023 results: EPS: NT$0.091 (up from NT$0.08 loss in FY 2022). Revenue: NT$1.33b (down 17% from FY 2022). Net income: NT$90.6m (up NT$171.1m from FY 2022). Profit margin: 6.8% (up from net loss in FY 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance. Announcement • Mar 12
Genes Tech Group Holdings Company Limited to Report Fiscal Year 2023 Final Results on Mar 21, 2024 Genes Tech Group Holdings Company Limited announced that they will report fiscal year 2023 final results on Mar 21, 2024 New Risk • Feb 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Market cap is less than US$10m (HK$59.0m market cap, or US$7.54m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Nov 01
Genes Tech Group Holdings Company Limited to Report Nine Months, 2023 Results on Nov 10, 2023 Genes Tech Group Holdings Company Limited announced that they will report nine months, 2023 results on Nov 10, 2023 New Risk • Oct 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$76.0m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.7% operating cash flow to total debt). Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (HK$76.0m market cap, or US$9.71m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Aug 13
Second quarter 2023 earnings released: EPS: NT$0.048 (vs NT$0.05 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.048 (down from NT$0.05 in 2Q 2022). Revenue: NT$429.6m (up 19% from 2Q 2022). Net income: NT$47.7m (down 4.1% from 2Q 2022). Profit margin: 11% (down from 14% in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Announcement • Aug 03
Genes Tech Group Holdings Company Limited to Report First Half, 2023 Results on Aug 11, 2023 Genes Tech Group Holdings Company Limited announced that they will report first half, 2023 results on Aug 11, 2023 Buying Opportunity • Jul 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 9.1%. The fair value is estimated to be HK$0.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Jun 29
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be HK$0.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • May 18
Now 23% undervalued Over the last 90 days, the stock is up 39%. The fair value is estimated to be HK$0.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • May 13
First quarter 2023 earnings released: EPS: NT$0.029 (vs NT$0.024 in 1Q 2022) First quarter 2023 results: EPS: NT$0.029 (up from NT$0.024 in 1Q 2022). Revenue: NT$319.9m (up 35% from 1Q 2022). Net income: NT$28.9m (up 22% from 1Q 2022). Profit margin: 9.0% (down from 10.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 24
Full year 2022 earnings released: NT$0.08 loss per share (vs NT$0.079 profit in FY 2021) Full year 2022 results: NT$0.08 loss per share (down from NT$0.079 profit in FY 2021). Revenue: NT$1.60b (up 6.8% from FY 2021). Net loss: NT$80.4m (down 201% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Buying Opportunity • Feb 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 35%. The fair value is estimated to be HK$0.099, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 26%. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: NT$0.05 (vs NT$0.015 in 2Q 2021) Second quarter 2022 results: EPS: NT$0.05 (up from NT$0.015 in 2Q 2021). Revenue: NT$359.9m (down 8.9% from 2Q 2021). Net income: NT$49.8m (up 222% from 2Q 2021). Profit margin: 14% (up from 3.9% in 2Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Aug 03
Genes Tech Group Holdings Company Limited to Report First Half, 2022 Results on Aug 11, 2022 Genes Tech Group Holdings Company Limited announced that they will report first half, 2022 results on Aug 11, 2022 Announcement • May 25
Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 23, 2022 Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 23, 2022, at 11:00 Taipei Standard Time. Location: No.80, Baotai 3rd Road, Zhubei City Hsinchu County Taiwan Agenda: To receive the audited consolidated financial statements of the company and the reports of the directors and auditors for the year ended 31 December 2021; to re-elect Ms. Wei Hung-Li as executive director; to re-elect Mr. Hsiao Hsi-Mao as executive director; to re-elect Mr. Kam, Eddie Shing Cheuk as independent non-executive director; to re-elect Mr. Cheng Chun Shing as independent non-executive director; to authorize the board of directors of the company to fix the respective directors' remuneration; to re-appoint PricewaterhouseCoopers as the auditor of the company and to authorize the board of directors of the Company to fix their remuneration; and to consider others. Announcement • May 12
Genes Tech Group Holdings Company Limited Announces the Resignation of Lin Yen-Po as Executive Director The board of directors of Genes Tech Group Holdings Company Limited announced that Mr. Lin Yen-Po has tendered his resignation as an executive director of the Company with effect from 10 May 2022 due to pursuance of his career development. Reported Earnings • May 11
First quarter 2022 earnings released: EPS: NT$0.024 (vs NT$0.031 in 1Q 2021) First quarter 2022 results: EPS: NT$0.024 (down from NT$0.031 in 1Q 2021). Revenue: NT$236.7m (down 43% from 1Q 2021). Net income: NT$23.7m (down 24% from 1Q 2021). Profit margin: 10.0% (up from 7.5% in 1Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 16% per year. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Eddie Kam was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: NT$0.079 (vs NT$0.14 in FY 2020) Full year 2021 results: EPS: NT$0.079 (down from NT$0.14 in FY 2020). Revenue: NT$1.50b (flat on FY 2020). Net income: NT$79.4m (down 45% from FY 2020). Profit margin: 5.3% (down from 9.6% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 7% per year. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS NT$0.034 (vs NT$0.018 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$381.6m (up 11% from 3Q 2020). Net income: NT$34.3m (up 93% from 3Q 2020). Profit margin: 9.0% (up from 5.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS NT$0.016 (vs NT$0.039 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$394.9m (down 14% from 2Q 2020). Net income: NT$15.4m (down 60% from 2Q 2020). Profit margin: 3.9% (down from 8.5% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Executive Departure • Jul 13
Deputy GM of Customer Service Division & Executive Director Chiang-Shen Fan has left the company On the 1st of July, Chiang-Shen Fan's tenure as Deputy GM of Customer Service Division & Executive Director ended after 4.9 years in the role. As of March 2021, Chiang-Shen still personally held 2.93m shares (HK$725k worth at the time). Chiang-Shen is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 10.33 years. Upcoming Dividend • Jun 23
Upcoming dividend of HK$0.012 per share Eligible shareholders must have bought the stock before 30 June 2021. Payment date: 15 October 2021. Trailing yield: 4.8%. Lower than top quartile of Hong Kong dividend payers (6.1%). Higher than average of industry peers (1.6%). Announcement • May 27
Genes Tech Group Holdings Company Limited Proposes Declare Final Dividend for the Year Ended 31 December 2020 Genes Tech Group Holdings Company Limited at the AGM to be held on June 25, 2021, proposed declare a final dividend of HKD 0.012 per share for the year ended 31 December 2020. Reported Earnings • May 16
First quarter 2021 earnings released: EPS NT$0.031 (vs NT$0.057 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$413.7m (up 7.1% from 1Q 2020). Net income: NT$31.2m (down 45% from 1Q 2020). Profit margin: 7.5% (down from 15% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Mar 19
Genes Tech Group Holdings Company Limited Recommends Final Dividend for the Year Ended 31 December 2020, Payable on or Before 15 October 2021 The Board of Genes Tech Group Holdings Company Limited has recommended the payment of a final dividend of HKD 0.012 per share in respect of the year ended 31 December 2020 (2019: Nil). The Proposed Final Dividend will be paid to shareholders whose names appear on the Register of Members of the Company on 7 July 2021, of which the aggregate amounts of the Proposed Final Dividend is approximately HKD 12,000,000, if the Proposal Final Dividend is approved by the shareholders of the Company at the forth coming Annual General Meeting (2021 AGM). The Proposed Final Dividend is expected to be paid on or before 15 October 2021. Announcement • Mar 18
Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 25, 2021 Genes Tech Group Holdings Company Limited, Annual General Meeting, Jun 25, 2021. Agenda: To approve final dividend for the year ended 31 December 2020. Reported Earnings • Mar 18
Full year 2020 earnings released: EPS NT$0.14 (vs NT$0.18 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: NT$1.50b (down 22% from FY 2019). Net income: NT$144.2m (down 20% from FY 2019). Profit margin: 9.6% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Mar 06
Genes Tech Group Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 17, 2021 Genes Tech Group Holdings Company Limited announced that they will report fiscal year 2020 results on Mar 17, 2021 Is New 90 Day High Low • Nov 30
New 90-day low: HK$0.24 The company is down 11% from its price of HK$0.27 on 01 September 2020. The Hong Kong market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 15% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: EPS NT$0.018 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$345.3m (down 26% from 3Q 2019). Net income: NT$17.8m (down 39% from 3Q 2019). Profit margin: 5.1% (down from 6.2% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Announcement • Nov 01
Genes Tech Group Holdings Company Limited to Report Nine Months, 2020 Results on Nov 11, 2020 Genes Tech Group Holdings Company Limited announced that they will report nine months, 2020 results on Nov 11, 2020 Announcement • Aug 01
Genes Tech Group Holdings Company Limited to Report First Half, 2020 Results on Aug 12, 2020 Genes Tech Group Holdings Company Limited announced that they will report first half, 2020 results on Aug 12, 2020 